Prophylaxis of catheter-related bacteremia using tissue plasminogen activator - Tobramycin locks

Ali Mirza Onder, Jayanthi Chandar, Anthony Billings, Nancy Simon, JoAnn A. Gonzalez, Denise Francoeur, Carolyn Abitbol, Gaston E Zilleruelo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

This retrospective study was designed to investigate the effectiveness of tissue plasminogen activator - tobramycin antibiotic lock solutions (TPA/tobra ABLs) for prophylaxis of catheter-related bacteremia (CRB) in high-risk children on long-term hemodialysis. During the first 6 months (Era 1), the high-risk group was defined. These patients received TPA/ tobra ABL prophylaxis after every hemodialysis treatment for the next 6 months (Era 2). The prophylaxis regimen was applied once a week for the third 6-months period (Era 3). Primary endpoints were CRB and infection-free catheter survival. There were 16,412 catheter days, and 95 cases of CRB in 43 children. The incidence of CRB was 5.8/1,000 catheter days. Significant decrease in the incidence of CRB was observed when prophylactic TPA/tobra ABL was used in the high-risk group (P = 0.0201). There was a tendency for less CRB when prophylactic ABL was applied after every hemodialysis session compared with once a week (P = 0.0947). The catheters in the high-risk group had shorter survival times than those in the average-risk group in Era 1 (P < 0.0001). However, both the overall and infection-free survival of the catheters in the high-risk group significantly improved while the patients were receiving TPA/tobra ABL prophylaxis, becoming similar to the outcomes of the catheters in the average-risk group and exhibiting statistically non-significant differences (P = 0.5571 and P = 0.9711, respectively). In conclusion, the TPA/tobra ABLs may effectively reduce the rate of CRB, and this may prolong both the overall and infection-free survival times of the catheters in the high-risk group.

Original languageEnglish
Pages (from-to)2233-2243
Number of pages11
JournalPediatric Nephrology
Volume24
Issue number11
DOIs
StatePublished - Jul 10 2009

Fingerprint

Tobramycin
Tissue Plasminogen Activator
Bacteremia
Catheters
Anti-Bacterial Agents
Renal Dialysis
Catheter-Related Infections
Survival
Incidence
Infection

Keywords

  • Antibiotic lock solutions
  • Catheter survival
  • Catheter-related bacteremia
  • Children
  • Tissue plasminogen activator

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Onder, A. M., Chandar, J., Billings, A., Simon, N., Gonzalez, J. A., Francoeur, D., ... Zilleruelo, G. E. (2009). Prophylaxis of catheter-related bacteremia using tissue plasminogen activator - Tobramycin locks. Pediatric Nephrology, 24(11), 2233-2243. https://doi.org/10.1007/s00467-009-1235-5

Prophylaxis of catheter-related bacteremia using tissue plasminogen activator - Tobramycin locks. / Onder, Ali Mirza; Chandar, Jayanthi; Billings, Anthony; Simon, Nancy; Gonzalez, JoAnn A.; Francoeur, Denise; Abitbol, Carolyn; Zilleruelo, Gaston E.

In: Pediatric Nephrology, Vol. 24, No. 11, 10.07.2009, p. 2233-2243.

Research output: Contribution to journalArticle

Onder, AM, Chandar, J, Billings, A, Simon, N, Gonzalez, JA, Francoeur, D, Abitbol, C & Zilleruelo, GE 2009, 'Prophylaxis of catheter-related bacteremia using tissue plasminogen activator - Tobramycin locks', Pediatric Nephrology, vol. 24, no. 11, pp. 2233-2243. https://doi.org/10.1007/s00467-009-1235-5
Onder, Ali Mirza ; Chandar, Jayanthi ; Billings, Anthony ; Simon, Nancy ; Gonzalez, JoAnn A. ; Francoeur, Denise ; Abitbol, Carolyn ; Zilleruelo, Gaston E. / Prophylaxis of catheter-related bacteremia using tissue plasminogen activator - Tobramycin locks. In: Pediatric Nephrology. 2009 ; Vol. 24, No. 11. pp. 2233-2243.
@article{e01d22c356e442a39978657212e7bfaa,
title = "Prophylaxis of catheter-related bacteremia using tissue plasminogen activator - Tobramycin locks",
abstract = "This retrospective study was designed to investigate the effectiveness of tissue plasminogen activator - tobramycin antibiotic lock solutions (TPA/tobra ABLs) for prophylaxis of catheter-related bacteremia (CRB) in high-risk children on long-term hemodialysis. During the first 6 months (Era 1), the high-risk group was defined. These patients received TPA/ tobra ABL prophylaxis after every hemodialysis treatment for the next 6 months (Era 2). The prophylaxis regimen was applied once a week for the third 6-months period (Era 3). Primary endpoints were CRB and infection-free catheter survival. There were 16,412 catheter days, and 95 cases of CRB in 43 children. The incidence of CRB was 5.8/1,000 catheter days. Significant decrease in the incidence of CRB was observed when prophylactic TPA/tobra ABL was used in the high-risk group (P = 0.0201). There was a tendency for less CRB when prophylactic ABL was applied after every hemodialysis session compared with once a week (P = 0.0947). The catheters in the high-risk group had shorter survival times than those in the average-risk group in Era 1 (P < 0.0001). However, both the overall and infection-free survival of the catheters in the high-risk group significantly improved while the patients were receiving TPA/tobra ABL prophylaxis, becoming similar to the outcomes of the catheters in the average-risk group and exhibiting statistically non-significant differences (P = 0.5571 and P = 0.9711, respectively). In conclusion, the TPA/tobra ABLs may effectively reduce the rate of CRB, and this may prolong both the overall and infection-free survival times of the catheters in the high-risk group.",
keywords = "Antibiotic lock solutions, Catheter survival, Catheter-related bacteremia, Children, Tissue plasminogen activator",
author = "Onder, {Ali Mirza} and Jayanthi Chandar and Anthony Billings and Nancy Simon and Gonzalez, {JoAnn A.} and Denise Francoeur and Carolyn Abitbol and Zilleruelo, {Gaston E}",
year = "2009",
month = "7",
day = "10",
doi = "10.1007/s00467-009-1235-5",
language = "English",
volume = "24",
pages = "2233--2243",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Prophylaxis of catheter-related bacteremia using tissue plasminogen activator - Tobramycin locks

AU - Onder, Ali Mirza

AU - Chandar, Jayanthi

AU - Billings, Anthony

AU - Simon, Nancy

AU - Gonzalez, JoAnn A.

AU - Francoeur, Denise

AU - Abitbol, Carolyn

AU - Zilleruelo, Gaston E

PY - 2009/7/10

Y1 - 2009/7/10

N2 - This retrospective study was designed to investigate the effectiveness of tissue plasminogen activator - tobramycin antibiotic lock solutions (TPA/tobra ABLs) for prophylaxis of catheter-related bacteremia (CRB) in high-risk children on long-term hemodialysis. During the first 6 months (Era 1), the high-risk group was defined. These patients received TPA/ tobra ABL prophylaxis after every hemodialysis treatment for the next 6 months (Era 2). The prophylaxis regimen was applied once a week for the third 6-months period (Era 3). Primary endpoints were CRB and infection-free catheter survival. There were 16,412 catheter days, and 95 cases of CRB in 43 children. The incidence of CRB was 5.8/1,000 catheter days. Significant decrease in the incidence of CRB was observed when prophylactic TPA/tobra ABL was used in the high-risk group (P = 0.0201). There was a tendency for less CRB when prophylactic ABL was applied after every hemodialysis session compared with once a week (P = 0.0947). The catheters in the high-risk group had shorter survival times than those in the average-risk group in Era 1 (P < 0.0001). However, both the overall and infection-free survival of the catheters in the high-risk group significantly improved while the patients were receiving TPA/tobra ABL prophylaxis, becoming similar to the outcomes of the catheters in the average-risk group and exhibiting statistically non-significant differences (P = 0.5571 and P = 0.9711, respectively). In conclusion, the TPA/tobra ABLs may effectively reduce the rate of CRB, and this may prolong both the overall and infection-free survival times of the catheters in the high-risk group.

AB - This retrospective study was designed to investigate the effectiveness of tissue plasminogen activator - tobramycin antibiotic lock solutions (TPA/tobra ABLs) for prophylaxis of catheter-related bacteremia (CRB) in high-risk children on long-term hemodialysis. During the first 6 months (Era 1), the high-risk group was defined. These patients received TPA/ tobra ABL prophylaxis after every hemodialysis treatment for the next 6 months (Era 2). The prophylaxis regimen was applied once a week for the third 6-months period (Era 3). Primary endpoints were CRB and infection-free catheter survival. There were 16,412 catheter days, and 95 cases of CRB in 43 children. The incidence of CRB was 5.8/1,000 catheter days. Significant decrease in the incidence of CRB was observed when prophylactic TPA/tobra ABL was used in the high-risk group (P = 0.0201). There was a tendency for less CRB when prophylactic ABL was applied after every hemodialysis session compared with once a week (P = 0.0947). The catheters in the high-risk group had shorter survival times than those in the average-risk group in Era 1 (P < 0.0001). However, both the overall and infection-free survival of the catheters in the high-risk group significantly improved while the patients were receiving TPA/tobra ABL prophylaxis, becoming similar to the outcomes of the catheters in the average-risk group and exhibiting statistically non-significant differences (P = 0.5571 and P = 0.9711, respectively). In conclusion, the TPA/tobra ABLs may effectively reduce the rate of CRB, and this may prolong both the overall and infection-free survival times of the catheters in the high-risk group.

KW - Antibiotic lock solutions

KW - Catheter survival

KW - Catheter-related bacteremia

KW - Children

KW - Tissue plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=70349743864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349743864&partnerID=8YFLogxK

U2 - 10.1007/s00467-009-1235-5

DO - 10.1007/s00467-009-1235-5

M3 - Article

C2 - 19590902

AN - SCOPUS:70349743864

VL - 24

SP - 2233

EP - 2243

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 11

ER -